An observational study in Overweight and Obesity, sponsored by Novo Nordisk A/S. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Novo Nordisk A/S · Observational
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia. The study will evaluate treatment patterns, adherence, quality of life, safety, and other health outcomes associated with semaglutide use in routine clinical practice. Information will be collected from data generated during standard clinical care, and no study-specific treatment or procedures will be required.
3,767 studies on the registry are indexed under Overweight; 863 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 150 across 443 observational studies indexed under Overweight.
Browse Overweight studies →Novo Nordisk A/S is the lead sponsor of 1,400 studies on the registry; 102 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 98 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will recruit individuals who are receiving semaglutide for the management of overweight or obesity and who are enrolled in one of the Eucalyptus Digital Weight Loss Service (DWLS) programmes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults with overweight or obesity who will initiate semaglutide as part of routine clinical care through a digital weight management programme in Australia and will be followed for up to 12 months. Semaglutide will be prescribed by healthcare professionals according to routine clinical practice for the management of overweight or obesity.
Drug: Semaglutide
All decisions regarding treatment will be made at the sole discretion of the treating HCP in accordance with their usual practices. No study medication will be provided as part of the study.
Absolute change in body weight from baseline
Measured in kilograms (kg).
Time frame: 12 months (365 days ±14 days)
Percentage change in body weight from baseline
Measured in percent (%) change from baseline.
Time frame: 12 months (365 days ±14 days)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2028, 16 months later.
Of 164 observational studies under Overweight, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 98. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.